| Drug ID: | Drug18 |
|---|---|
| Drug Name: | Fluconazole |
| CID: | 3365 |
| DrugBank ID: | DB00196 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02765256 |
| Molecular Formula: | C13H12F2N6O |
| Molecular Weight: | 306.27 g/mol |
| Isomeric SMILES: | C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O |
| Synonyms: | fluconazole; 86386-73-4; Biozolene; Fluconazol; Elazor; Biocanol; Zoltec; Fluconazolum; Flucazol; Flucostat |
| Phase 0: | 3 |
| Phase 1: | 74 |
| Phase 2: | 39 |
| Phase 3: | 53 |
| Phase 4: | 23 |
| Description: | Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt159 | 3365 | Fluconazole | 3641571 | ERG11 | Candida albicans SC5314 | Inhibitor | |
| dt160 | 3365 | Fluconazole | 1577 | CYP3A5 | Homo sapiens (human) | 25429674 | Inhibitor |
| dt161 | 3365 | Fluconazole | 1576 | CYP3A4 | Homo sapiens (human) | Inhibitor | |
| dt162 | 3365 | Fluconazole | 1559 | CYP2C9 | Homo sapiens (human) | Inhibitor | |
| dt163 | 3365 | Fluconazole | 1557 | CYP2C19 | Homo sapiens (human) | Inhibitor | |
| dt164 | 3365 | Fluconazole | 5243 | ABCB1 | Homo sapiens (human) | 28355970 | Inhibitor |
| dt165 | 3365 | Fluconazole | 1559 | CYP2C9 | Homo sapiens (human) | None | |
| dt166 | 3365 | Fluconazole | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt167 | 3365 | Fluconazole | 1557 | CYP2C19 | Homo sapiens (human) | None | |
| dt168 | 3365 | Fluconazole | 1544 | CYP1A2 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02765256 | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease | PHASE2 | COMPLETED | University of Pennsylvania | Crohn's Disease | DRUG: Fluconazole|DRUG: Vancomycin|DRUG: Neomycin… | Details |
| NCT06274554 | A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease | PHASE3 | Recruiting | Weill Medical College of Cornell University | Crohn's Disease;Inflammatory Bowel Diseases | Drug: Fluconazole;Drug: Placebo;Biological: IL-23… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Oral Fluconazole Therapy in Patients With Active Ulcerative Colitis Who Have De…
PMID: 34516459
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: There is an emerging role of fungal dysbiosis in the pathogenesis of inflammatory bowel disease. Prevalence of Candida in patients with a…
Berberine disrupts the high-affinity iron transport system to reverse the fluco…
PMID: 39929396
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Invasive fungal infection is usually caused by Candida albicans infection, which has a high incidence rate and mortality in critically ill patients. …
Non-Toxic and Ultra-Small Biosilver Nanoclusters Trigger Apoptotic Cell Death i…
PMID: 30769763
Year: 2019
Relationship Type:
Mechanism
Score: 6.5
BACKGROUND AND AIMS: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation, which …